Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure

American Heart Journal

Volumn 170, Issue 5, 2015, Pages 951-960

  Reed, Shelby D ^a,b   Neilson, Matthew P ^c   Gardner, Matthew ^a   Li, Yanhong ^a   Briggs, Andrew H ^c   Polsky, Daniel E ^d   Graham, Felicia L ^a   Bowers, Margaret T ^e   Paul, Sara C ^f   Granger, Bradi B ^e   Schulman, Kevin A ^a,b   Whellan, David J ^g   Riegel, Barbara ^d   Levy, Wayne C ^h  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e DUKE UNIVERSITY   (United States)

^f Catawba Valley Cardiology   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ASSESSMENT OF HUMANS; CAUSE OF DEATH; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; EXTERNAL VALIDITY; HEALTH CARE COST; HEALTH CARE SYSTEM; HEART FAILURE; HOSPITALIZATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; PATIENT CARE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SEATTLE HEART FAILURE MODEL SCORE; SIMULATION; SURVIVAL; COST BENEFIT ANALYSIS; DISEASE MANAGEMENT; ECONOMIC MODEL; ECONOMICS; INTERNET;

COST-BENEFIT ANALYSIS; DISEASE MANAGEMENT; HEART FAILURE; HUMANS; INTERNET; MODELS, ECONOMIC; QUALITY OF LIFE;

EID: 84954304502     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2015.08.015     Document Type: Article

References (28)

1. S. Maru, J. Byrnes, J.A. Whitty, and et al. Systematic review of model-based analyses reporting the cost-effectiveness and cost-utility of cardiovascular disease management programs Eur J Cardiovasc Nurs 14 2015 26 33
2. B. Smith, P.F. Hughes-Cromwick, E. Forkner, and et al. Cost-effectiveness of telephonic disease management in heart failure Am J Manag Care 14 2008 106 115
3. G. Miller, S. Randolph, E. Forkner, and et al. Long-term cost-effectiveness of disease management in systolic heart failure Med Decis Making 29 2009 325 333
4. S.D. Reed, Y. Li, S. Kamble, and et al. Introduction of the TEAM-HF Costing Tool: a user-friendly spreadsheet program to estimate costs of providing patient-centered interventions Circ Cardiovasc Qual Outcomes 5 2012 113 119
5. W.C. Levy, D. Mozaffarian, D.T. Linker, and et al. The Seattle Heart Failure Model: prediction of survival in heart failure Circulation 113 2006 1424 1433
6. A.C. Alba, T. Agoritsas, M. Jankowski, and et al. Risk prediction models for mortality in ambulatory patients with heart failure: a systematic review Circ Heart Fail 6 2013 881 889
7. Gissi-HF Investigators L. Tavazzi, A.P. Maggioni, and et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial Lancet 372 2008 1231 1239
8. J. Kjekshus, E. Apetrei, V. Barrios, and et al. Rosuvastatin in older patients with systolic heart failure N Engl J Med 357 2007 2248 2261
9. V.C. Lee, D.C. Rhew, M. Dylan, and et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction Ann Intern Med 141 2004 693 704
10. A. Kuenzli, H.C. Bucher, I. Anand, and et al. Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure PLoS One 5 2010 e9946
11. M.C. Shibata, R.T. Tsuyuki, and N. Wiebe The effects of angiotensin-receptor blockers on mortality and morbidity in heart failure: a systematic review Int J Clin Pract 62 2008 1397 1402
12. R. Garg, and S. Yusuf Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials JAMA 273 1995 1450 1456
13. F. Zannad, J.J. McMurray, H. Krum, and et al. Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
14. J.A. Ezekowitz, and F.A. McAlister Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials Eur Heart J 30 2009 469 477
15. S.D. Reed, Y. Li, M.E. Dunlap, and et al. Inpatient resource use and medical costs in the last year of life by mode of death in HF-ACTION Am J Cardiol 110 2012 1150 1155
16. S.D. Reed, Y. Li, S.J. Ellis, and et al. Seattle Heart Failure Model scores significantly predict medical resource use and costs in HF-ACTION Presented at: 15th Annual Scientific Meeting of the Heart Failure Society of America; September 2011; Boston, Massachusetts 2011
17. Y. Li, M. Neilson, D.J. Whellan, and et al. Associations between Seattle Heart Failure Model scores and health utilities: findings from HF-ACTION J Card Fail 19 2013 311 316
18. B. Granger, H. Bosworth, A. Hernandez, and et al. Results of the Chronic Heart Failure Intervention To Improve Medication Adherence (CHIME) Study: a randomized self-management intervention in high risk non-adherent patients Presented at: American Heart Association Scientific Sessions; November 8, 2013; Dallas, Texas 2013
19. C.M. O'Connor, D.J. Whellan, K.L. Lee, and et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial JAMA 301 2009 1439 1450
20. D.B. Mark, C.L. Nelson, K.J. Anstrom, and et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Circulation 114 2006 135 142
21. P.A. Cowper, E.R. DeLong, D.J. Whellan, and et al. Economic effects of beta-blocker therapy in patients with heart failure Am J Med 116 2004 104 111
22. D.C. Chan, P.A. Heidenreich, M.C. Weinstein, and et al. Heart failure disease management programs: a cost-effectiveness analysis Am Heart J 155 2008 332 338
23. S. Maru, J. Byrnes, M.J. Carrington, and et al. Economic implications of cardiovascular disease management programs: moving beyond one-off experiments Expert Rev Pharmacoecon Outcomes Res 15 2015 657 666
24. D.M. Eddy, W. Hollingworth, J.J. Caro, and et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7 Value Health 15 2012 843 850
25. A.J. Palmer, Mount Hood 5 Modeling Group, P. Clarke, and et al. Computer modeling of diabetes and its complications: a report on the fifth Mount Hood Challenge Meeting Value Health 16 2013 670 685
26. E.M. Pelletier, B. Shim, R. Ben-Joseph, and et al. Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis Pharmacoeconomics 27 2009 479 490
27. J.A. Ladapo, G. David, C.L. Gunnarsson, and et al. Healthcare utilization and expenditures in patients with atrial fibrillation treated with catheter ablation J Cardiovasc Electrophysiol 23 2012 1 8
28. J. Chyu, G.C. Fonarow, C.H. Tseng, and et al. Four-variable risk model in men and women with heart failure Circ Heart Fail 7 2014 88 95